Simply Wall St.
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib Combo - Has The Bull Case Changed?
đ
AI Sentiment
Positive
7/10
Cogent Biosciences Inc. News
Latest updates and market news for COGT
3 news
Jan 17 - Jan 23, 2026
Page 1
MT Newswires
Cogent Biosciences Says FDA to Accept Bezuclastinib NDA Submission Under Real-Time Oncology Review
â
AI Sentiment
Neutral
5/10
GlobeNewswire
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
đ
AI Sentiment
Highly Positive
10/10
Share this news page